These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 21714585)

  • 1. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
    Agouridis AP; Tsimihodimos V; Filippatos TD; Dimitriou AA; Tellis CC; Elisaf MS; Mikhailidis DP; Tselepis AD
    Expert Opin Pharmacother; 2011 Dec; 12(17):2605-11. PubMed ID: 21714585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels.
    Makariou SE; Liberopoulos EN; Agouridis AP; Challa A; Elisaf M
    J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):382-6. PubMed ID: 22431864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome.
    Agouridis AP; Kostapanos MS; Tsimihodimos V; Kostara C; Mikhailidis DP; Bairaktari ET; Tselepis AD; Elisaf MS
    Int J Clin Pract; 2012 Sep; 66(9):843-53. PubMed ID: 22897461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). cmb@bcm.tmc.edu.
    Ballantyne CM; Davidson MH; Setze CM; Kelly MT
    J Clin Lipidol; 2011; 5(5):401-7. PubMed ID: 21981842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
    Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
    J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia.
    Agouridis AP; Tsimihodimos V; Filippatos TD; Tselepis AD; Elisaf MS
    Lipids; 2011 Jun; 46(6):521-8. PubMed ID: 21327725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
    Kei A; Liberopoulos E; Tellis K; Rizzo M; Elisaf M; Tselepis A
    Eur J Clin Invest; 2013 Jul; 43(7):698-707. PubMed ID: 23600368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
    Kei A; Tellis C; Liberopoulos E; Tselepis A; Elisaf M
    Cardiovasc Ther; 2014 Aug; 32(4):139-46. PubMed ID: 24618208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
    Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
    Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
    Weinstein DL; Williams LA; Carlson DM; Kelly MT; Burns KM; Setze CM; Lele A; Stolzenbach JC
    Clin Ther; 2013 Aug; 35(8):1186-98. PubMed ID: 23891363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia.
    Moutzouri E; Liberopoulos EN; Tellis CC; Milionis HJ; Tselepis AD; Elisaf MS
    Atherosclerosis; 2013 Nov; 231(1):8-14. PubMed ID: 24125402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
    Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
    Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
    Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
    Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein.
    Burmeister JE; Miltersteiner DR; Campos BM
    J Nephrol; 2009; 22(1):83-9. PubMed ID: 19229822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study.
    Anagnostis P; Selalmatzidou D; Polyzos SA; Panagiotou A; Slavakis A; Panagiotidou A; Athyros VG; Karagiannis A; Mikhailidis DP; Kita M
    Int J Clin Pract; 2011 Jun; 65(6):679-83. PubMed ID: 21564441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining rosuvastatin with angiotensin-receptor blockers of different PPARγ-activating capacity: effects on high-density lipoprotein subfractions and associated enzymes.
    Rizos CV; Liberopoulos EN; Tellis K; DiNicolantonio JJ; Tselepis AD; Elisaf MS
    Angiology; 2015 Jan; 66(1):36-42. PubMed ID: 24288364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol.
    Bergheanu SC; Van Tol A; Dallinga-Thie GM; Liem A; Dunselman PH; Van der Bom JG; Jukema JW
    Curr Med Res Opin; 2007 Sep; 23(9):2235-40. PubMed ID: 17692153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of switch to the highest dose of rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia.
    Kei A; Liberopoulos EN; Mikhailidis DP; Elisaf M
    Int J Clin Pract; 2013 May; 67(5):412-9. PubMed ID: 23510018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.